Clinical Trials /

Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma



This research study is designed to see if Capecitabine and Lenvatinib in combination with external radiation therapy are effective in treating locally advanced rectal adenocarcinoma in patients who have not yet had surgery, and what the best dosage is.

Related Conditions:
  • Rectal Adenocarcinoma
Recruiting Status:

Active, not recruiting


Phase 1

Trial Eligibility



  • Brief Title: Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma
  • Official Title: Phase I Study of Pre-operative Capecitabine and Lenvatinib With External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma

Clinical Trial IDs

  • ORG STUDY ID: MCC-18646
  • NCT ID: NCT02935309


  • Rectal Cancer
  • Rectal Adenocarcinoma


LenvatinibE7080Pre-Surgery Chemotherapy/Radiotherapy
CapecitabineTeva-Capecitabine, XelodaPre-Surgery Chemotherapy/Radiotherapy


This research study is designed to see if Capecitabine and Lenvatinib in combination with external radiation therapy are effective in treating locally advanced rectal adenocarcinoma in patients who have not yet had surgery, and what the best dosage is.

Trial Arms

Pre-Surgery Chemotherapy/RadiotherapyExperimentalPre-surgery chemotherapy and external radiation therapy. Dose escalation of Lenvatinib; fixed dose Capecitabine; Radiotherapy. Lenvatinib and capecitabine will be started on day 1 with radiation and will be discontinued on the last day of radiation. Surgical resection should occur between 6 - 10 weeks after the participant completes preoperative lenvatinib, capecitabine, and radiation therapy. Postoperative chemotherapy after surgery will be given at investigator's discretion.
  • Lenvatinib
  • Capecitabine

Eligibility Criteria

        Inclusion Criteria:

          -  Histologically (archival tissue) confirmed adenocarcinoma of the rectum that begins
             within 12 cm of the anal verge as determined by sigmoidoscopy and/or colonoscopy with
             no evidence of distant metastasis.

          -  Locally advanced rectal cancer determined by any of the following features: 1.) Fixed
             or immobile tumor on physical exam and/or; 2.) T3 disease with invasion through the
             muscularis propria as defined by transrectal ultrasound, CT or MRI; 3.) T4 disease
             with invasion of adjacent structures such as pelvic sidewall, sacrum, pelvis, bladder
             and/or prostate as determined appropriate imaging modalities such as ultrasound, CT or
             MRI; 4.) Any T with + N on CT scan/MRI or transrectal ultrasound.

          -  Age equal to or greater than 18 years

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.

          -  Adequate bone marrow, liver and renal function.

          -  Women of childbearing potential must have a negative serum pregnancy test performed
             within 7 days prior to the start of treatment.

          -  Women of childbearing potential and men must agree to use adequate contraception
             (barrier method of birth control) prior to study entry and for the duration of study
             participation. Men should use adequate birth control for at least 3 months after the
             last administration of lenvatinib.

          -  Ability to understand and the willingness to sign a written informed consent. A signed
             informed consent must be obtained prior to any study specific procedures.

        Exclusion Criteria:

          -  Cardiac disease: Congestive heart failure > class II New York Heart Association
             (NYHA). Participants must not have unstable angina (anginal symptoms at rest) or new
             onset angina (began within the last 3 months) or myocardial infarction within the past
             6 months.

          -  Previous pelvic irradiation therapy.

          -  Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.

          -  Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic
             pressure > 90 mmHg, despite optimal medical management.

          -  Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C.

          -  Active clinically serious infection > CTCAE Grade 2.

          -  Thrombotic or embolic events such as a cerebrovascular accident including transient
             ischemic, attacks, deep vein thrombosis (DVT) within the past 6 months.

          -  Bleeding or thrombotic disorders or use of anticoagulants, such as warfarin, or
             similar agents requiring therapeutic international normalized ration (INR) monitoring.
             (Treatment with low molecular weight heparin (LMWH) is allowed).

          -  Active malignancy except for non-melanoma skin cancer or in situ cervical cancer or
             treated non-pelvic cancer from which the patient has been continuously disease free
             more than 3 years.

          -  Marked baseline prolongation of QT/QTc interval (QTc interval ≥ 500 msec) using the
             Fridericia method (QTc = QT/RR0.33) for QTc analysis.

          -  Greater than 30 mg/dL on urine analysis. Patients with >30 mg/dL on urine analysis on
             urine analysis will undergo 24-hour urine collection for quantitative assessment of
             proteinuria. Patients with 24-hour protein ≥1 g/24 hours will be ineligible.

          -  Needing medical attention for serious bleeding in past 4 weeks.

          -  Previous chemotherapy except for antiangiogenic agent or tyrosine kinase inhibitor
             (TKI) will be allowed as long as it is more than 5 years.

          -  Major surgeries within 3 weeks of starting chemotherapy.

          -  Evidence or history of bleeding diathesis.

          -  Use of St. John's Wort or rifampin.

          -  Known or suspected allergy to lenvatinib or any agent given in the course of this

          -  Any condition that impairs participant's ability to swallow whole pills.

          -  Any malabsorption problem.

          -  Medical need for the continued use of potent inhibitors/inducers of CYP3A4.

          -  Creatinine clearance not within study guidelines.
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Maximum Tolerated Dose (MTD)
Time Frame:Up to 6 months
Safety Issue:
Description:MTD of lenvatinib used in combination with capecitabine and external beam radiation as neoadjuvant therapy for patients with locally advanced rectal carcinoma. The MTD of lenvatinib will be defined as the highest dose level at which no more than 1 out of 6 participants experiences dose-limiting toxicity (DLT). DLT: Any of the hematology or non-hematologic toxicities noted in Table 3 of the protocol, considered to be at least possibly related to lenvatinib and/or capecitabine.

Secondary Outcome Measures

Measure:Rate of Pathologic Response
Time Frame:Up to 36 months
Safety Issue:
Description:Pathologic response rate after pre-operative therapy and surgery. Pathologic Complete Response (pCR) will be defined as pathologic proof of a complete response based on histologic evaluation of the resected specimen.
Measure:Occurrence of Treatment Related Adverse Events
Time Frame:Up to 36 months
Safety Issue:
Description:To further define safety profile of the combination. Adverse events will be graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0.


Phase:Phase 1
Primary Purpose:Interventional
Overall Status:Active, not recruiting
Lead Sponsor:H. Lee Moffitt Cancer Center and Research Institute

Trial Keywords

  • rectum
  • transrectal
  • carcinoma

Last Updated

August 16, 2021